Etrolizumab Demonstrated no Difference Among Doses in Symptomatic and Endoscopic-Based Evaluation of Remission in Anti-TNF-α Naïve Patients in a Post hoc Analysis of the Phase 2 Ulcerative Colitis Trial (Eucalyptus)